Ascletis Pharma
Manufacturing · China · 201-500 Employees
View Company Info for Free
Overview
Headquarters
Building D 198 Qidi Rd 12TH Fl, Hipark, ...Phone Number
+86 57185389730Website
www.ascletis.comRevenue
$7.8 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Ascletis Pharma
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including small molecules and peptides for chronic weight management. Ascletis aims to address global unmet medical needs and is listed on the Hong Kong Stock Exchange. Their target clients include healthcare providers and patients seeking effective treatments for metabolic and immune diseases.Explore more
Ascletis Pharma Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ascletis Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Ascletis Pharma is spiking on competitors!
Click to see if Ascletis Pharma had a recent Job posting/layoffs
Product Launch: Get notified when Ascletis Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Ascletis Pharma
Ascletis Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Ascletis Pharma has new funding data
Check if Ascletis Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Ascletis Pharma recently announced quarterly report
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined Ascletis Pharma as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Ascletis Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Ascletis Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Ascletis Pharma.
Ascletis Pharma financials insights
Gather financial insights about Ascletis Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Series A
$100M
2015
Private Equity
$35M
Unspecified
$20M
2017
Series B
$100M
Ascletis Pharma Tech Stack
A closer look at the technologies used by Ascletis Pharma
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Executive Move
Board of Directors
Executive Move
Board of Directors
Promotion
Executive Move
John Gargiulo has been promoted to the role of Chief Business Officer.
New Hire
Executive Move
Ascletis Pharma News & Media
Ascletis Announces Initiation of Phase I Study in U.S. for Oral Amylin Receptor Peptide Agonist ASC36 for the Treatment of Obesity
- This trial marks the fourth Phase I peptide study for Ascletis this year. - ASC36 oral tablets achieved absolute oral bioavailability of 6% to 8% at steady state in non-human primate (NHP) studies utilizing Ascletis' proprietary Peptide Oral Transport ENhancement Technology (POTENT). - ASC36 oral tablets reduced mean body weight up to 13.2% from baseline after once-daily dosing for seven days in NHPs. - ASC36 subcutaneous (SQ) injection demonstrated approximately 32% and 91% greaterAscletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs
HONG KONG, Sept. 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that, the ordinary shares of the Company (the "Shares"), which trade on The Stock Exchange of Hong Kong Limited (the "HK Stock Exchange"), have been included in the list of eligible securities...Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg)...Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management
- Expected to enroll approximately 4,600 participants with obesity or overweight across two pivotal trials (AURORA-1 and AURORA-2) in the U.S., Europe, and Canada. - Global Phase III clinical program to investigate efficacy and safety of three maintenance doses (20 mg, 40 mg, and 60 mg) over 72 weeks in participants with obesity or overweight without type 2 diabetes (AURORA-1) and with type 2 diabetes (AURORA-2). - Topline data from the AURORA Phase III clinical
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ascletis Pharma
Sign Up For FreeTo access detailed company insights
Ascletis Pharma Inc. is a fully integrated biotechnology company dedicated to developing and commercializing innovative therapeutics for metabolic diseases. The company utilizes advanced technologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and Ultra-Long-Acting Platform to create a range of drug candidates, including... Read More
